1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-6-ol | 908288-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-6-ol
• 英文别名: 1-(2,2-Dimethylpropyl)-1h-1,2,3-benzotriazol-6-ol；3-(2,2-dimethylpropyl)benzotriazol-5-ol
• CAS: 908288-74-4
• 化学式: C₁₁H₁₅N₃O
• 分子量: 205.26
• InChiKey: IOYFLXNMNPGKMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  50.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-ol 、 1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-6-ol 在 溴 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 生成 4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-ol 、 7-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-6-ol
  参考文献：
  名称：

  WO2006/91496

  摘要：

  公开号：

文献信息

• Benzazole Potentiators of Metabotropic Glutatmate Receptors
  申请人：Govek Steven P.

  公开号：US20080176904A1

  公开（公告）日：2008-07-24

  The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并咪唑化合物，其是代谢型谷氨酸受体增强剂，包括mGluR2受体，并且在与谷氨酸功能紊乱相关的神经学和精神疾病以及代谢型谷氨酸受体参与的疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的这些疾病中的使用。
• Benzazole potentiators of metabotropic glutamate receptors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07960417B2

  公开（公告）日：2011-06-14

  The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并咪唑化合物，它们是代谢型谷氨酸受体的增强剂，包括mGluR2受体，适用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及代谢型谷氨酸受体参与的疾病。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗代谢型谷氨酸受体参与的疾病。
• BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merck & Co., Inc.

  公开号：EP1855670A2

  公开（公告）日：2007-11-21
• US7960417B2
  申请人：——

  公开号：US7960417B2

  公开（公告）日：2011-06-14
• [EN] BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] POTENTIALISATEURS DE BENZAZOLE DE RECEPTEURS DE GLUTAMATE METABOTROPIQUE
  申请人：MERCK & CO INC

  公开号：WO2006091496A2

  公开（公告）日：2006-08-31

  [EN] The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
  [FR] L'invention se rapporte à des composés de benzazole qui sont des potentialisateurs de récepteurs de glutamate métabotropique, y compris le récepteur mGluR2, et qui sont utiles dans le traitement ou la prévention de troubles neurologiques et psychiatriques associés au dysfonctionnement du glutamate et aux maladies dans lesquelles les récepteurs de glutamate métabotropique sont impliqués. Cette invention concerne aussi des compositions pharmaceutiques contenant ces composés, ainsi que l'utilisation de ces composés et compositions dans la prévention ou le traitement des maladies dans lesquelles les récepteurs de glutamate métabotropique sont impliqués.